Virus vectors and methods of making and administering the same
OwnerJoseph Rabinowitz, Richard Samulski +1inventors
InventorsJoseph Rabinowitz, Richard Samulski, Weidong Xiao
Life of this patent
Estimating the term…
Abstract
The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.
Claims45
A chimeric virus particle comprising:
- (a) a chimeric adeno-associated virus serotype-2 (AAV2) capsid comprising a chimeric capsid protein comprising at least one capsid region from AAV1;
- and
- (b) a nucleic acid comprising 5′ and 3′ AAV inverted terminal repeats and at least one heterologous nucleotide sequence, wherein said nucleic acid is packaged within the chimeric parvovirus capsid.
A chimeric virus particle comprising:
- (a) a chimeric adeno-associated virus serotype-2 (AAV2) capsid comprising at least one AAV1 capsid region;
- and
- (b) a nucleic acid comprising 5′ and 3′ AAV inverted terminal repeats and at least one heterologous nucleotide sequence, wherein said nucleic acid is packaged within the chimeric AAV2 capsid.
An isolated nucleic acid encoding the adeno-associated virus serotype-2 (AAV2) cap genes and AAV rep genes, wherein the AAV2 cap genes encode a chimeric AAV2 capsid comprising at least one AAV1 capsid region.
A method of producing a chimeric virus particle, the method comprising:
- providing a cell with chimeric adeno-associated virus serotype-2 (AAV2) cap genes, AAV rep genes, a nucleic acid comprising 5′ and 3′ AAV inverted terminal repeats and at least one heterologous nucleotide sequence, and helper functions for generating a productive AAV infection, wherein the chimeric AAV cap genes comprise at least one nucleic acid sequence from AAV1 cap genes such that the chimeric AAV2 cap genes encode a chimeric AAV2 capsid comprising at least one AAV1 capsid region;
- and
- allowing assembly of the chimeric virus particles.
42-49. (canceled)
51-58. (canceled)
Dependencies are inferred from the claim text.